Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
FSRH response to Welsh ‘Relationship and sexuality education (RSE) statutory guidance and code’ consultation.
FSRH response to consultation ‘Transforming the public health system: reforming the public health system for the challenges of our times’ by the Department of Health and Social Care (DHSC).
FSRH response to NHS Confederation survey on leadership in Integrated Care Systems
Joint FSRH and RCOG response to the Health and Social Care Committee Inquiry into the White Paper “Integration and Innovation: working together to improve health and social care”.
We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Lovima, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
We respond to the consultation by The Medicines and Healthcare Products Regulatory Agency (MHRA) on whether to reclassify Hana, a progestogen-only contraceptive pill, as Pharmacy (P) medicine.
The Department of Health and Social Care is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in England.
The Welsh Government is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in Wales.
We make the case for long-term, sustainable investment in Public Health, Education and Training.
FSRH's response to NHS England / Improvement’s consultation on proposed legislative options to further develop Integrated Care Systems (ICS).
